Partner Roche announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study, demonstrating that investigational antisense drug sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria relative to placebo at 37 weeks (P<0.0001). The treatment was well tolerated with no new safety signals. Ionis Pharmaceuticals is an RNA-targeted biotechnology company developing medicines for serious diseases.
